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Umbilical cord tissue represents a unique source of cells with potential for cell therapy applications for multiple
diseases. Human umbilical tissue-derived cells (hUTC) are a developmentally early stage, homogenous popu-
lation of cells that are HLA-ABC dim, HLA-DR negative, and lack expression of co-stimulatory molecules in the
unactivated state. The lack of HLA-DR and co-stimulatory molecule expression on unactivated hUTC may
account for their reduced immunogenicity, facilitating their use in allogeneic settings. However, such ap-
proaches could be confounded by host innate cells such as natural killer (NK) cells. Here, we evaluate in vitro
NK cell interactions with hUTC and compare them with human mesenchymal stem cells (MSC). Our investi-
gations show that hUTC suppress NK activation, through prostaglandin-E2 secretion in a contact-independent
manner. Prestimulation of hUTC or human MSC with interferon gamma (IFN-g) induced expression of the
tryptophan degrading enzyme indoleamine 2, 3 dioxygenase, facilitating enhanced suppression. However,
resting NK cells of different killer immunoglobulin-like receptor haplotypes did not kill hUTC or MSC; only
activated NK cells had the ability to kill nonstimulated hUTC and, to a lesser extent, MSC. The cell killing
process involved signaling through the NKG2D receptor and the perforin/granzyme pathway; this was sup-
ported by CD54 (ICAM-1) expression by hUTC. IFN-g-stimulated hUTC or hMSC were less susceptible to NK
killing; in this case, protection was associated with elevated HLA-ABC expression. These data delineate the
different mechanisms in a two-way interaction between NK cells and two distinct cell therapies, hUTC or hMSC,
and how these interactions may influence their clinical applications.
Introduction
Human umbilical tissue-derived cells (hUTC) have beenreported as having potential for cellular repair [1–4].
Immunogenicity studies revealed that a single injection of
porcine unactivated umbilical cord tissue-derived cells (UTC)
across a full major histocompatibility complex (MHC) barrier
does not elicit a detectable adaptive immune response [5].
Animals injected once either systemically or subcutaneously
with unactivated UTC had no detectable alloantibody pro-
duction and a normal rejection pattern following in vivo skin
graft challenge [5]. Mesenchymal stem cells (MSC) derived
from bone marrow have been inferred nonimmunogenic
based on their well-described immunomodulatory properties
[6–8]. These properties have led to their development as cell
therapeutics for inflammatory, transplantation, and autoim-
mune disorders [8–10]. These immunomodulatory properties
allow allogeneic MSC to be deployed to limit graft rejection
after hematopoietic stem cell transplantation [11] and the use
of allogeneic MSC for the treatment of graft-versus-host dis-
ease (GvHD) [11,12]. Thus, these cells can be developed for
allogeneic cell therapy in a manner that is characterized,
standardized, and scaled for regulatory approval. Despite
recent mechanistic advances [13], the comprehensive under-
standing of immune modulatory capabilities of hUTC or MSC
remain to be tested. In particular, there is an incomplete un-
derstanding of how allogeneic cell therapy products interact
with the cells of the recipient’s innate and adaptive immune
systems. An understanding of the interaction between po-
tential allogeneic cell therapy products and recipient immune
cells will be crucial for the rational development of effective
and commercially attractive allogeneic cell-based therapies.
Natural killer (NK) cells represent a major lymphoid ef-
fector cell population of the innate immune arsenal [14].
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They play key roles in the recognition and destruction of
virus-infected or aberrant host cells [14,15]. These cells shape
subsequent adaptive immunity through secretion of cytokines,
particularly interferon gamma (IFN-g) [16]. Earlier, we and
others have shown that adult human bone marrow-derived
MSC are immunosuppressive, and counter-intuitively, that
suppression can be enhanced or ‘‘licensed’’ by inflamma-
tory mediators such as IFN-g [7,17]. Thus, IFN-g does not
break, but enhances the immunomodulatory capacity of
MSC. Given the time frame of development for adaptive
immunity, if licensing of cell therapy occurs in vivo, then
NK cells are a likely source of the licensing signal (IFN-g)
for MSC in vivo.
Human NK cell function is regulated through the expres-
sion of a large repertoire of inhibitory and activating receptors
[18], and activation is regulated by a balance of inhibitory and
stimulatory signals. Cells lacking or with impaired expression
of HLA-ABC are recognized and killed by NK cells [19]. In
mice, NK1.1 and Ly49 receptors are important for murine NK
cell function; however, these are not relevant for studies of
human cells. The CD94 chaperone/NKG2 receptor family (A–
D) is more important in the human context, and this complex
recognizes the nonclassical HLA, HLA-E [16]. The other key
signal group is the polymorphic killer immunoglobulin-like
receptors (KIRs), which interact with HLA-ABC ligands in
humans and deliver either inhibitory or stimulatory signals
depending on the cytoplasmic KIR tail. Although polymor-
phic, KIR haplotypes can be classified into two broad types:
type A and type B, both of which can suppress cytolysis. In
contrast, NK-mediated killing of target cells depends on acti-
vatory signaling involving specific ligand–receptor interac-
tions [18,20]. NK receptors involved in cytolysis are the natural
cytotoxicity receptors (NCR) NKp30, NKp44, and NKp46, and
the nonpolymorphic NK receptors NKG2D and DNAM-1. The
ligands for these include the MHC Class I-related A and B
molecules (MICA/B), UL16-binding proteins (ULBP), the po-
liovirus receptor (PVR), and Nectin-2 [20,21]. Therefore, NK
cells possess the machinery to either activate or kill allogeneic
cells, potentially enhancing or confounding cell therapies.
Rational and successful development of allogeneic cell
therapies will require an understanding of the interaction
between these cells and NK cells to determine longevity of
therapeutic efficacy, cell dose, and frequency of administra-
tion. Recent reports have delivered apparently contradictory
results. Mesenchymal cells derived from bone marrow or cells
derived from umbilical cord seem to suppress NK cell pro-
liferation and function in vitro [22–24]. However, IL-2- or IL-
15-activated autologous and allogeneic NK cells were capable
of killing MSC and fetal-derived stem cells [25,26]. Interest-
ingly, IFN-g-stimulated MSC and fetal stem cells were pro-
tected from NK cytolysis [25,26]. Thus, there is need for
clarification of two questions: (1) to what extent and by what
mechanisms do allogeneic hUTC or MSC cell therapy sup-
press activation of NK cells? and (2) to what extent and by
what mechanisms do NK cells kill allogeneic hUTC and MSC?
In the current study, we sought to characterize the inter-
action between hUTC and MSC with NK cells in vitro. We
show that hUTC or MSC suppress NK activation, and this is
enhanced by IFN-g prestimulation. This occurs through mul-
tiple mechanisms that depend on the activation state of the
cell. Resting NK cells do not kill allogeneic hUTC, whereas
activated NK cells can. hUTC can be partially protected from
such killing by previous activation or licensing. The mecha-
nisms for killing involved the exploitation of the NKG2D-
perforin/granzyme pathway. Overall, this study clarifies the
parameters and mechanisms by which hUTC and MSC in-
teract with a critical confounding influence on cell therapy
and suggest ways by which these can be overcome.
Materials and Methods
Isolation and culture of hUTC or MSC
The research was approved by the institutional review
boards and biological ethics committee of the National
University of Ireland, Maynooth. All human participants
gave written informed consent. Human MSC from two dif-
ferent donors were isolated and expanded from aspirates of
bone marrow by direct plating, as previously described
[27,28]. Cultures were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bo-
vine serum (PAA Laboratories GmbH) and 1% penicillin/
streptomycin (Sigma-Aldrich). When the cultures reached
80% confluence, cells were detached by treatment with 0.25%
trypsin/EDTA (Bio Sciences Ltd.) and re-cultured at 1 · 106
cells/175 cm2 tissue culture flask. The HLA haplotype of
donor #030 was HLA*A01/33, B51/58, Cw06/07; donor
#061 was HLA*A03/03, B07/35, Cw04/07. All MSC used
fulfilled the ISCT criteria and displayed typical surface
markers and tri-lineage differentiation capacity as previously
described. MSC were rigorously monitored for contaminat-
ing cell populations and were used in experiments at passage
7. hUTC were isolated and cultured as described [1] and
used at passage 11. In some experiments, hUTC or MSC were
cultured with 50 ng/mL rhIFN-g (Peprotech) for 48 h, to
generate IFN-g-stimulated hUTC or MSC.
Isolation and culture of NK cells
NK cells were isolated from the peripheral blood from a
panel of healthy donors using an NK cell isolation kit (Mil-
tenyi Biotec). Haplotype A and B donor NK cells were
identified by KIR genotyping (below), and NK cells from
representative donors were used in subsequent experiments.
Purified NK cells were either used directly or cultured with
100 U/mL rhIL-2 and 10 ng/mL rhIL-15 (Peprotech) for 48 h
in complete RPMI to obtain activated NK cells for cytotox-
icity assays.
Monoclonal antibodies and cytofluorometric
analysis
Antibodies used for flow cytometric labeling included
FITC-conjugated anti-human CD29, CD44, CD90, HLA-ABC,
CD31, CD94, and CD56; PE-conjugated anti-CD34, CD45,
CD106, CD117, HLA-DR, CD54, CD11b, HLA-E, CD155,
MICA/B, NKG2D, NKG2C, and NKp30; and APC-conjugated
anti-CD105, HLA-G, CD112, CD69, NKG2A, and NKp44
(eBioscience; or R&D systems). Isotype controls included
FITC, PE, or APC-conjugated mouse IgG1, IgG2a, or PE-
conjugated mouse IgG2b (eBioscience). For cell surface
labeling, cells were incubated with saturating amounts of
monoclonal antibodies or appropriate isotype controls
for 30 min at 4C. Cells were then washed five times
and examined by flow cytometry (FACScalibur; Becton
3004 NOONE ET AL.
Dickinson). Data were analyzed using Cellquest software
(Becton Dickinson).
Cytotoxicity assays
To test the lytic potential of NK cells against hUTC or
MSC, a commercial total cytotoxicity and apoptosis detection
kit was used. Briefly, NK cells (effector cells) were cultured
with 5(6)-carboxyfluorescein diacetate N-succinimidyl es-
ter (CFSE) labeled hUTC or MSC (target cells) at different
effector:target ratios for 4 h. Cells were then stained with
SR-FLICA poly-caspase apoptosis and 7-AAD reagent
(Immunochemistry Technologies LLC), which enabled the
detection of both early and late apoptotic cells, respec-
tively. The percentage of total cell cytotoxicity was then
determined. In some experiments, hUTC or MSC were
preincubated with anti-human CD54 (ICAM-1), or HLA-
ABC blocking antibodies (10 mg/mL) or mouse IgG1 con-
trol antibody (10 mg/mL) for 40 min before addition of NK
cells. In other experiments, rhIL-2 (100 U/mL)/rhIL-15
(10 ng/mL)-activated NK cells were cultured with anti-
human NK receptor blocking antibodies NKp30, NKp44,
or NKG2D (10–20 mg/mL) or mouse IgG1 control antibody
(10–20 mg/mL) for 30 min or with a granzyme B inhibitor
(Z-AAD-CMK; Enzo Life Sciences) at 50 mM or 100 mM for
45 min, before addition to hUTC or MSC. Concentrations
of blocking antibodies had been previously optimized.
Cytokine production
To evaluate NK activation in vitro, resting NK cells
(4 · 105) were cultured in a 96-well plate in complete RPMI
containing 100 U/mL rhIL-2 and 10 ng/mL rhIL-15 (Pepro-
tech), with or without hUTC or MSC at a 5:1 ratio for 48 h. In
some experiments, 0.4 mm transwell inserts (Cruinn Diag-
nostics Ltd.) were used to separate NK cells from hUTC or
MSC, and the prostaglandin inhibitor indomethacin (20 mM;
Sigma-Aldrich), IDO inhibitor 1-MLT (20 mM; Sigma-
Aldrich), anti-human TGFb1 (5 mg/mL; R&D Systems), or
control IgG (5 mg/mL; R&D Systems) were added to NK-
hUTC or MSC co-cultures. After incubation, supernatants
were harvested, and IFN-g (R&D Systems) and PGE2 (Cay-
man Chemical Company) production were assessed by
ELISA. TGFb1 was quantified by flow cytometry using the
FlowCytomix simplex kit (eBioscience).
KIR genotyping
Genomic DNA from NK cells was isolated using a
QIAamp DNA mini kit (Qiagen). The presence or absence of
specific KIR alleles was determined from 50–75 ng/ml DNA
by polymerase chain reaction (PCR)-sequence specific
priming (SSP) using a KIR Genotyping SSP kit (Bio Sciences
Ltd.), according to the manufacturer’s instructions. Type A
donors were discriminated from Type B by lack of expres-
sion of KIR2DL2, KIR2DS1,2,3, KIR2DS5, and KIR3DS1 and
expression of KIR2DS4 among others.
Real-time/reverse transcriptase PCR
Total RNA was extracted from cells using a Ribopure kit
(Ambion), and RNA was reverse transcribed to cDNA using
SUPERSCRIPT II reverse transcriptase (Invitrogen). cDNA
(1mg) was amplified in the presence of SYBR Green
PCR master mix (Invitrogen). Primers used are described in
Table 1.
Samples were run in duplicate, and accumulation of gene-
specific PCR products was measured continuously by means
of fluorescence detection over 36 cycles. Gene expression was
calculated relative to the endogenous control, and analysis
was performed using the 2 -DDCT method. cDNA (1mg) was
also analyzed for the expression of human IDO mRNA by
semi-quantitative reverse transcriptase (RT)-PCR. PCR prod-
ucts were resolved by 1.3% (w/v) agarose gel electrophoresis.
Statistical analysis
Statistical significance was assessed using Prism5 software
(GraphPad Software, Inc.). For group comparisons, data
were analyzed using one-way ANOVA, with Tukey’s mul-
tiple comparison test to measure significance. For other
comparisons, data were analyzed using the two-tailed Stu-
dent’s t-test. P-values of *P £ 0.05, **P £ 0.01, and ***P £ 0.001
were considered statistically significant.
Results
hUTC or MSC suppress NK activation,
which is enhanced by IFN-c stimulation
The capacity of hUTC or MSC to suppress NK activation
was explored in vitro. Differences in KIR haplotypes can affect
the outcome of hematopoietic stem cell transplantation [29]; for
that reason, it was speculated that mesenchymal-like cells
might differentially influence activation of NK cells from either
haplotype A or B donors. Therefore, NK cells from healthy
donors were typed for KIR alleles, and representative donors
representing the A or B haplotype were used. In order to de-
termine whether IFN-g-stimulated hUTC or MSC suppressed
NK activation in vitro, NK cells (haplotype A or B) were acti-
vated by a cocktail of IL-2/IL-15 and co-cultured with hUTC or
MSC. NK activation was assessed by cytokine production.
Human MSC potently suppressed NK activation, significantly
inhibiting IFN-g secretion from NK cells at all NK to MSC
ratios (Fig. 1). No difference was observed between NK cells
from different haplotype groups. hUTC also significantly
suppressed NK activation but only at a high hUTC concen-
tration (5:1 and 1:1), (Fig. 1C, F). Thus, unlike MSC, nonacti-
vated hUTC only suppress NK activation at high ratios.
Table 1. Primers Used for Reverse
Transcriptase–Polymerase Chain Reaction
Target Forward primer/reverse primer pairs
ULBP-1 5¢-AAGGCCTGGTGGATGAAAGGCC-3¢
5¢-AGGGTGAGGGGCTCAATGGGTAT-3¢
ULBP-2 5¢-GCCGCTACCAAGATCCTTCTGTGC-3¢
5¢-TCTGTGCTTTCCAGGCCGTTGTG-3¢
ULBP-3 5¢-GGCAACAGTGGTGTGAGGTCCA-3¢
5¢-CAGCCAGTTCCAGTCTGAGCCT-3¢
IDO 5¢-CGCTGTTGGAAATAGCTTC-3¢
5¢-CAGGACGTCAAAGCACTGAA-3¢
GAPDH 5¢-GGTGAAGGTCGGAGTCAACG-3¢
5¢-CAAAGTTGTCATGGATGACC-3¢
ULBP, UL16-binding proteins.
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IFN-g prestimulation of MSC enhances other immune
modulating capacities of MSC [7,17]. Interestingly, IFN-g
stimulation of both hUTC (ghUTC) and MSC (gMSC) sup-
pressed NK activation more effectively, and at lower con-
centrations than cells not stimulated with IFN-g (Fig. 1).
Since cells from haplotype A and B donors behaved in a
similar manner (Fig.1 and data not shown), all subsequent
data are representative for both haplotypes.
hUTC or MSC suppress NK activation through
prostaglandin secretion, and after IFN-c stimulation,
through additional mechanisms
In order to identify the factors involved in hUTC or MSC
suppression of NK activation, known mediators of sup-
pression were investigated. Prostaglandins are key media-
tors that are involved in other aspects of MSC-mediated
immune modulation [7,30]. Co-cultures of NK cells with
nonstimulated hUTC or MSC showed elevated quantities of
PGE2 (Fig. 2A). Prostaglandin secretion by hUTC or MSC
represented a strong candidate that might potentially medi-
ate suppression of NK activation, and we have previously
shown that MSC used in this study secrete PGE2 [7]. To test
this hypothesis, NK cell co-culture experiments were per-
formed with hUTC or MSC in the presence or absence of the
prostaglandin antagonist, indomethacin. Blocking prosta-
glandins with indomethacin restored NK-derived IFN-g
levels in hUTC or MSC co-cultures compared with non-
treated co-cultures (Fig. 2B). This effect is most profound in
hUTC, as blocking prostaglandins with indomethacin leads
to elevated IFN-g (Fig. 2B). This suggests that in the absence
of prostaglandins, hUTC behave similar to any other allo-
geneic cell and have an activatory effect. Further investiga-
tion revealed that suppression of NK activation through
PGE2 was contact independent, as IFN-g secretion from NK
cells was unchanged when the cells were separated by
transwells in the presence of indomethacin (Fig. 2C).
Stimulation of MSC with IFN-g alters expression of im-
munosuppressive mediators; in particular, IDO and TGFb1
have been implicated in this effect [7,31]. Therefore, the in-
fluence of these factors was examined in hUTC. Here, IFN-g
stimulation reduced PGE2 production from hUTC (Fig. 2A)
but increased expression of TGFb1 in prestimulated hUTC-
NK co-cultures and this was greater than that seen in MSC
co-cultures (Fig. 3A). IFN-g stimulation also induced ex-
pression of the enzyme IDO in hUTC or MSC (Fig. 3B).
Therefore, IFN-g-stimulated hUTC or MSC were co-cultured
with NK cells under activating conditions in the presence or
FIG. 1. IFN-g-stimulated
hUTC or MSC potently sup-
press NK activation com-
pared with nonstimulated
cells. Freshly isolated NK
cells from either haplotype A
(A–C) or haplotype B (D–F)
donors were stimulated with
IL-2 and IL-15 and co-cultured
with nonstimulated hUTC
or MSC or IFN-g-stimulated
ghUTC and gMSC for 48 h at
a ratio of 1:1–20:1 (NK:
MSC/HUTC). IFN-g levels
from supernatants of NK
cells co-cultured with donor
030 MSC (empty bar)/gMSC
(hatched bar) (A, D), donor
061 MSC/gMSC (B, E) or
hUTC and ghUTC (C, F)
were determined by ELISA.
Results are representative of
three independent experi-
ments and are shown as the
means – SE of triplicate sam-
ples. *P £ 0.05, ***P £ 0.001
(differences between acti-
vated NK cells and non-
stimulated hUTC or MSC or
IFN-g-stimulated hUTC or
MSC co-cultures). hUTC,
human umbilical tissue-
derived cells; NK, natural
killer; MSC, mesenchymal
stem cells; IFN-g, interferon
gamma.
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absence of antagonists for PGE2, IDO and/or a neutralizing
antibody for TGFb1. Blocking IDO and PGE2 partially re-
stored activation of NK cells in ghUTC or gMSC co-cultures
(Fig. 3C). Neutralizing TGFb1 only restored NK activation in
ghUTC co-cultures but had no effect on gMSC co-cultures
(Fig. 3C). Further investigation revealed that suppression of
NK activation through PGE2/IDO was also contact inde-
pendent, as activation of NK cells was unaffected by cell
separation and was only influenced by the presence of the
antagonists (Fig. 3D). However, activation of NK cells in
ghUTC or gMSC co-cultures was never fully restored, raising
the possibility that other factors may also contribute to
suppression. In summary, IFN-g stimulated MSC suppress
NK activation through prostaglandins and IDO, while IFN-
g- stimulated hUTC use additional mechanisms involving
TGFb1.
Activated NK cells lyse nonstimulated hUTC
or MSC but IFN-c-stimulated hUTC or MSC
are less susceptible to NK killing
NK cells are potent cytotoxic effectors that could influence
hUTC or MSC survival in vivo. Therefore, NK-mediated
killing of allogeneic hUTC or MSC was investigated. hUTC
or MSC targets were labeled with CFSE and co-cultured with
resting NK cells at different effector:to target ratios. Cyto-
toxic activity at 4 h was measured by flow cytometry. Pre-
viously, other groups have reported that resting NK cells
were unable to kill MSC [23,26]; thus, it was not surprising
that resting NK cells were also unable to lyse hUTC or MSC
but instead killed the leukemia cell line K562 at high effec-
tor:target cell ratios (Fig. 4A). Moreover, IFN-g stimulated
hUTC or MSC were not lysed by resting NK cells (Supple-
mentary Fig. S1; Supplementary Data are available online at
www.liebertpub.com/scd). However, during an inflamma-
tory response in vivo, NK cells might be activated at the site
of injury or pathology by the cytokine milieu. Therefore, the
capacity of activated NK cells to kill hUTC or MSC in vitro
was examined. Labeled hUTC or MSC were co-cultured with
IL-2/15-activated NK cells at different ratios, and cytotoxic
activity was measured. Activated NK cells readily lysed
K562 cells, and, to a lesser extent, MSC (Fig. 4B). In contrast,
hUTC were also highly susceptible to NK killing (Fig. 4B),
demonstrating that hUTC or human MSC are prone to de-
letion by activated NK cells, albeit at different sensitivities.
The role of IFN-g licensing or stimulation in the cell
populations was also explored. Stimulation of MSC by IFN-g
rendered these cells less sensitive to deletion and even pro-
tected them from lysis at some ratios (Fig. 4B, C). However,
ghUTC were lysed by activated NK cells at comparable
levels to K562 (Fig. 4B, C). Importantly, at a ratio of 5:1 and
1:1, ghUTC (Fig. 4B) were less susceptible to NK cell killing
than hUTC (Fig. 4C). Thus, IFN-g renders allogeneic hUTC
and MSC more resistant to activated NK cytotoxicity.
NK inhibitory ligands are up-regulated
in IFN-c-stimulated hUTC or MSC, while activating
ligands are reduced
Our observation that IFN-g-stimulated hUTC or MSC
were less susceptible to NK cytotoxicity than unstimulated
hUTC or MSC led us to examine potential NK activating
FIG. 2. Nonstimulated hUTC or MSC suppress NK activa-
tion through prostaglandin secretion. (A) Presence of PGE2 in
co-cultures of activated (IL-2 and IL-15) NK with non-
stimulated or IFN-g- stimulated hUTC or MSC at 1:0.2
(NK:MSC) ratio after 48 h. Data represent the means – SE from
three combined experiments of duplicate samples. *P £ 0.05,
**P £ 0.01 (nonstimulated hUTC or MSC co-cultures and IFN-g-
stimulated hUTC or MSC co-cultures). (B) NK activation as
measured by IFN-g levels from NK: hUTC or MSC co-cultures
in the presence or absence of the prostaglandin inhibitor, in-
domethacin (20mM). (C) Transwell assay measuring NK acti-
vation (IFN-g levels) from NK: hUTC or MSC co-cultures in the
presence or absence of indomethacin. Results are representative
of three independent experiments and are shown as the
means – SE of triplicate samples. ***P £ 0.001 (differences be-
tween activated NK cells and hUTC or MSC co-cultures) and
###P £ 0.001 (NK-hUTC or MSC co-cultures compared with in-
hibitor-treated co-cultures).
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ligands expressed in nonstimulated versus IFN-g stimulated
cells. Essentially nonstimulated hUTC or MSC showed
comparable levels of expression for most NK ligands (Table 2
and Supplementary Fig. S2A–C). The exception was HLA-
ABC (MHC Class I) expression, which was lower in hUTC
than in MSC (Table 2). IFN-g stimulation of both cells ele-
vated this expression (Table 2). gMSC displayed increased
HLA-E, the nonclassical MHC ligand for the NK inhibitory
receptor CD94/NKG2A (Table 2), and both gMSC and
ghUTC showed reduced levels of activating ligands ULBP1–
3 (Supplementary Fig. S2A–C), recognized by NKG2D [20].
Therefore, prestimulation of hUTC or MSC with IFN-g leads
to increased expression of inhibitory HLA-ABC (MHC Class
I) molecules and reduced expression of activating ligands for
NKG2D.
Activated NK cells kill hUTC or MSC through
the NKG2D perforin/granzyme pathway
The potential NK (activating) receptors that may be in-
volved in killing hUTC or MSC—NKp30, NKp44, and
NKG2D were investigated. These activating receptors are
known to be up-regulated in activated NK cells [20], and this
was the case here also (data not shown). These receptors
were blocked using previously validated monoclonal anti-
bodies. Blocking NKp30 or NKp44 in activated NK cells did
not reduce the killing of hUTC or MSC; however, neutral-
izing NKG2D significantly decreased cytotoxicity of both
cells (Fig. 5A–C). Signaling through NKG2D activates the
perforin/granzyme cytolytic pathway [21]. This pathway is
enhanced by the ligation of adhesion molecules such as
CD54 (ICAM-1) in target cells with LFA-1 in NK cells. hUTC
expressed higher levels of CD54 than MSC (Fig. 5G–I). The
simultaneous blocking of CD54 and NKG2D significantly
reduced cytotoxicity of hUTC, compared with blocking with
NKG2D alone (Fig. 5F). Blocking CD54 on MSC had no ad-
ditional effect on reduced cytotoxicity. These results were
supported by the treatment of NK cells with a granzyme B
inhibitor. NK cell killing of MSC was abolished by inhibitor
treatment (Fig. 5J). Taken together, these data suggest that
NK killing of hUTC or MSC occurs via the NKG2D/Per-
forin/granzyme pathway and that this is supported by high
ICAM-1/CD54 on hUTC.
MHC-Class I protects IFN-c-stimulated hUTC
or MSC from NK killing
IFN-g stimulated hUTC or MSC were more resistant to NK
cytotoxicity than nonstimulated hUTC or MSC (Fig. 4B, C). It
was speculated that this protection may be linked to the
FIG. 3. Stimulated hUTC or MSC suppress NK activation through prostaglandin, IDO, or TGFb. (A) TGFb1 (pg/mL) is
present in supernatant from activated (IL-2/15) NK cells co-cultured with IFN-g-stimulated hUTC or MSC (1:0.2 ratio) for
48 h, detected by ELISA. Data represent means – SE from three combined experiments of duplicate samples. ***P £ 0.001
(difference between IFN-g-stimulated hUTC compared with IFN-g-stimulated MSC co-cultures). (B) IDO mRNA at 48 h was
detected in nonstimulated hUTC or MSC or IFN-g-stimulated hUTC or MSC by RT-PCR. (C) Activation (measured by IFN-g)
of NK cells co-cultured with IFN-g-stimulated hUTC or MSC in the presence of indomethacin (20 mM), 1-MLT (20mM), anti-
human TGFb1 (5mg/mL), or control antibody (5mg/mL). (D) as (C) but performed in transwell culture preventing NK/
hUTC or MSC contact. Results are representative of three independent experiments and are shown as the means – SE of
triplicate samples. ***P £ 0.001 (differences between activated NK cells and IFN-g-stimulated hUTC or MSC co-cultures),
##P £ 0.01, ###P £ 0.001 (NK-hUTC or MSC co-cultures compared with inhibitor-treated co-cultures) and $$$P £ 0.001 (indo
treated NK-hUTC co-cultures compared with indo + 1-MLT-treated NK-hUTC co-cultures). RT-PCR, reverse transcriptase–
polymerase chain reaction.
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increased MHC Class I detected in stimulated ghUTC/gMSC
(Table 2). Therefore, further neutralization studies were per-
formed. Blocking MHC Class I (anti-HLA-ABC) in ghUTC/
gMSC significantly increased cytotoxicity compared with
control-treated cultures (Fig. 6A), confirming that MHC class I
protects licensed hUTC or MSC from NK killing. In line with
others [26], blocking MHC class I in nonstimulated hUTC or
MSC did not alter the cytotoxicity profile of these cells (data
not shown). Further investigation revealed that the concen-
tration of IFN-g influenced MHC Class I expression in hUTC
or MSC, and this correlated to reduced cytotoxicity (Fig. 6B,
C). However, high MHC Class I expression did not fully
protect ghUTC/gMSC from NK cytolysis (Fig. 6B, C).
NKG2D and CD54 again played a role in NK killing of
IFN-g stimulated hUTC or MSC. Blocking NKG2D reduced
killing of ghUTC and gMSC (Fig. 6D–F). Neutralizing CD54
in ghUTC (but not gMSC) reduced killing by NK cells but
had no additional inhibitory effect on cytotoxicity mediated
through NKG2D (Fig. 6D–F). Therefore, it is reasonable to
assume that elevated MHC-Class I contributes to the pro-
tection of IFN-g-stimulated hUTC and MSC from NK killing.
The killing that is observed occurs via the NKG2D receptor
and, in the case of hUTC, this is supported by CD54/ICAM-1
expression.
Discussion
Allogeneic MSC are potent immunomodulators [8,13],
offering a promising cell therapy for the treatment of human
diseases. However, the interactions between NK cells and
these cell therapeutics are not well understood. hUTC have
also been shown to exhibit significant repartive properties
[1–4] and are a developmentally early cell type that can be
expanded to greater extents before reaching senescence [1].
hUTC can be isolated with ease from umbilical tissue and
represent a more readily available cell type than human bone
marrow-derived MSC. In this study, the interactions between
candidate human cell therapy technologies and NK cells
were defined, and the mechanistic pathways were identified.
hUTC or MSC suppress allogeneic NK activation, through
prostaglandin secretion, without a requirement for direct cell
FIG. 4. NK cells lyse nonstimulated hUTC or MSC but IFN-
g renders hUTC or MSC less susceptible to NK killing. (A)
Resting NK cells were used as effector cells against non-
stimulated CFSE-labeled 030 MSC, 061 MSC, hUTC or K562
cells at different E:T ratios. Activated NK cells were used as
effector cells against (B) nonstimulated CFSE-labeled hUTC or
MSC or (C) IFN-g-stimulated CFSE-labeled ghUTC or MSC at
different E:T ratios. Cytolytic activity was measured by flow
cytometry after 4 h of incubation. Data represent a combina-
tion of three independent experiments. **P £ 0.01, ***P £ 0.001
(differences between NK-mediated killing of nonstimulated
hUTC and MSC or NK-mediated killing of IFN-g-stimulated
hUTC and MSC). CFSE, 5(6)-carboxyfluorescein diacetate N-
succinimidyl ester; E:T, effector:target.
Table 2. Natural Killer Ligands Expressed
by Nonstimulated or IFN-g-Stimulated hUTC or MSC
Expression (MFI)a
Marker hUTC chUTC MSCb cMSC
HLA-ABC + (80) + + (730) + (170) + + (870)
HLA-E - - - + (18)
HLA-G - - - -
Nectin-2 (CD112) - - - -
PVR (CD153) + (40) + (40) + (60) + (70)
MIC-A/B - - - -
aPeak expression < 10 considered negative; 10–100 scored + ; 100–
1,000 scored + + ; gMSC and ghUTC represent IFN-g stimulated
MSC and hUTC respectively.
bData shown for donor 030, similar data seen for donor 061 and
repeated thrice.
ND, not determined; hUTC, human umbilical tissue-derived cells;
MSC, mesenchymal stem cells; IFN-g, interferon gamma; PVR,
poliovirus receptor; MFI, mean fluorescence intensity.
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contact. Suppression extends to the two major KIR types of
the NK cell identified. IFN-g, which licenses MSC in other
situations, stimulates hUTC and MSC expression of IDO,
enhancing suppression of NK activation. Resting NK cells
did not kill hUTC or MSC; however, activated NK cells killed
these targets. Killing was mediated through the NKG2D-
perforin granzyme pathway and was supported by CD54
(ICAM-1) expression by hUTC. IFN-g stimulation protected
MSC and, to a lesser extent, hUTC from NK killing, and this
was associated with MHC class I expression by the cell. Data
from clinical trials have highlighted the beneficial effects that
mesenchymal cell-based therapies exert in the treatment of
GvHD, Crohn’s disease, and myocardial infarction [32–34].
The use of allogeneic products also enables scalable and
controllable cell technologies to be developed [35], making
them very attractive for large-scale manufacturing. Never-
theless, limitations remain to be addressed in relation to
widespread clinical use, with the longevity of therapeutically
administered cells in vivo being one contentious issue [36].
The most likely immune cells to confound early hUTC/MSC
survival are NK cells. Their reported capacity to kill alloge-
neic stem cells [26,37] makes them a cell type that cannot be
FIG. 5. NKG2D activation plays a role in
NK-mediated cytotoxicity of hUTC or MSC.
Cytolytic activity was measured by flow cy-
tometry after 4 h of incubation of IL-2/15-
activated NK cells cultured with 030 MSC
(A, D), 061 MSC (B, E), or hUTC (C, F) at
1:0.2 (NK:MSC/hUTC) ratio. NK receptors
(A–C) or NKG2D/CD54 (E–F) were blocked
by neutralizing antibodies or isotype control.
Data represent a combination of three to five
independent experiments. *P £ 0.05,
**P £ 0.01, ***P £ 0.001 (differences between
isotype control and neutralization anti-
bodies), and #P £ 0.05 (difference NKG2D/
CD54 vs. NKG2D alone neutralization).
CD54 (gray line) expression by nonstimulated
030 MSC (G), 061 MSC (H), or hUTC (I); solid
histogram represents isotype control. Fluor-
escence (peak MFI given on histogram)
measured by flow cytometry at 48 h. ( J) Ac-
tivated NK killing of nonstimulated hUTC or
MSC in the presence or absence of Granzyme
B inhibitor. Data representative of triplicate
experiments – SE. **P £ 0.01, ***P £ 0.001 (dif-
ferences between NK cytotoxicity of MSC
compared with hUTC) and ##P £ 0.01,
###P £ 0.001 (differences between granzyme B
inhibitor-treated and nontreated cells). MFI,
mean fluorescence intensity.
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ignored when designing treatment regimens, as their influ-
ence could be critical to the success of cell-based therapies.
hUTC or human allogeneic MSC suppressed NK activa-
tion, and this extended to NK cells from donors of different
KIR types. Suppression did not require direct cell contact but
occurred through prostaglandin production by the non-
hematopoietic cells. This is in agreement with some other
reports [23,24,38], but, importantly, demonstrates that hu-
man polymorphisms in KIR alleles are unlikely to confound
cell therapy. We observed that both IFN-g-stimulated hUTC
and MSC proved to be more potent suppressors of NK ac-
tivation in vitro than nonstimulated cells. This study defines
the role of trophic mediators in IFN-g - licensed mesenchy-
mal-like cell suppression of NK activation.
IFN-g induced hUTC or human MSC expression of IDO,
and this supported PGE2 in suppression of NK activation.
This parallels our previous observation that MSC-derived
kynurenine (the tryptophan breakdown product created by
IDO action, which can be measured by HPLC detection)
suppresses human T-cell activation [7]. Interestingly, in ad-
dition, IFN-g-stimulated hUTC relied on TGFb1 for this ef-
fect. Despite some similarities between hUTC and MSC, clear
differences were seen between these cell types. Differences
may be related to their source, intrinsic properties, and/or
the isolation and expansion processes for these different cell
types. This study defines suppression more precisely than
heretofore; however, other soluble factors may be involved
in licensed hUTC or MSC suppression of NK cells, as cyto-
kine production was never fully restored in these co-culture
blocking studies. One potential candidate is soluble HLA-G,
which has been shown to be involved in induced pluripotent
cell suppression of NK activation [38].
A number of previous reports have shown that MSC can
inhibit NK cyotoxicity [23,24,39]. However, these examined
resting NK cells, cultured with activating IL-2/15 in the
presence of mesenchymal-like cells [23,24,38]. Our data
suggest that in these scenarios the mesenchymal populations
were able to exert their suppressive effects before the NK
cells were activated. However, cell-based therapies are likely
to be used to treat diseases that are associated with profound
inflammation, and in environments in which NK cells are
likely to be active. Accordingly, for effective therapy, hUTC
FIG. 6. MHC-Class I protects IFN-g-stimulated hUTC or MSC from NK killing. Neutralizing MHC class I (A) on MSC or
hUTC increases cytotoxicity compared with isotype control antibody. IFN-g-stimulated hUTC or MSC (ghUTC or MSC) were
labeled with CFSE and cultured alone (no Ab) or with saturating amounts of anti-human HLA-ABC, CD54, or mouse IgG1
control antibody before addition to cytolytic assays with activated NK cells (1:0.2 effector: target ratio). Killing of IFN-g-
stimulated 061 gMSC (B) or ghUTC (C) was also determined following varied levels of IFN-g prestimulation (0, 0.5, 5, and
50 ng/mL) and correlated to HLA-ABC expression. Prestimulation was for 48 h before NK co-culture. Cytotoxicity by
activated NK cells was also determined in the presence or absence of neutralizing antibodies for NKG2D, and/or CD54, or
appropriate control antibody for IFN-g-stimulated 030 gMSC (D), 061 gMSC (E), or ghUTC (F). Data represent mean – SE of a
combination of three independent experiments. *P £ 0.05, **P £ 0.01, and ***P £ 0.001. Comparisons are with isotype control
antibodies in all neutralization studies. MHC, major histocompatibility complex.
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or MSC may need to survive clearance by activated NK
populations. Importantly, we and others [25,26,40] have
shown that IFN-g - licensed allogeneic hUTC or MSC are
superior to nonstimulated cells in avoiding cytolysis by ac-
tivated NK cells. Here, we show that activated NK cell killing
of nonstimulated hUTC or MSC involved the perforin/
granzyme pathway and signaling via the NKG2D receptor.
We observed some differences from Spaggiari et al. [26]; in
our hands, NKp30 did not influence killing of hUTC or MSC.
This difference is minor and likely due to heterogeneity in
MSC. Indeed, we noted significant differences between
nonstimulated hUTC and MSC. hUTC expressed higher
levels of CD54 than MSC and contributed to NK cytotoxicity
of hUTC, supporting the NKG2D effect. Interestingly, CD54
has been shown to play a role in the NK killing of other bone
marrow stromal cells [37], but was not supportive of the
cytotoxicity of our adult MSC. This has an important im-
plication, as it suggests that cell therapy products which
express high levels of CD54 (or selected for this to improve
homing) may be more readily deleted by NK cells. Gother-
strom et al. showed that fetal MSC were more sensitive to
NK killing than adult MSC [25]. However, they showed that
fetal multipotent cells were killed through the TNF-related
apoptosis inducing ligand (TRAIL) pathway, whereas adult
multipotent cells were killed via FAS ligand [25]. In contrast,
our results indicate that hUTC or MSC from different donors
were killed via the perforin/granzyme pathway. Blocking
TRAIL and/or FAS-L in activated NK cells of different KIR
types did not significantly reduce cytotoxicity of our cells
(data not shown). Multipotent cells are often considered
precursor types to the cells here, and TRAIL/FAS-L have
developmental roles that are consistent with these differ-
ences. However, we do not rule out other unidentified acti-
vators of the perforin/granzyme pathway contributing to
NK killing of hUTC or MSC, as cytotoxicity was only par-
tially blocked by neutralizing CD54 and NKG2D.
IFN-g stimulation of hUTC or MSC increased expression
of inhibitory MHC Class I and down-regulated activating
ligands (ULBPs) in hUTC or MSC. Furthermore, MHC Class
I (HLA-ABC) was essential for the protection of IFN-g-
stimulated hUTC or MSC, and increasing levels of MHC
Class I inversely correlated to cytotoxicity. It is now clear
that hMSC have the capacity to migrate to damaged tissues
and exert immunomodulatory effects on an array of immune
cells in target tissues via paracrine and/or cell-to-cell contact
mechanisms [30,41,42]. Infusion of IFN-g-stimulated MSC in
animal models of GvHD, allergic airway disease, and chronic
obstructive pulmonary disease (COPD) have shown im-
provements in the efficacy of the cell-based therapy
[17,43,44]. These beneficial effects have been linked to IFN-g-
stimulated MSC immunomodulators, including prostaglan-
dins, TGFb1, IL-10, and IDO [6,7,45,46], and establishing the
exact factors involved will be critical to their use in vivo.
In demonstrating the parameters and mechanisms of hUTC
or MSC suppression of NK activation, the susceptibility and
mechanisms of killing, and the key role played by IFN-g, this
study helps resolve the conflicting reports concerning MSC/
NK interaction. For example, while some reports have sug-
gested a role for the FAS/FASL pathway [25], the present
study confirms a previous study that the main pathway in-
volved in NK cytolysis of adult MSC requires perforin/
granzyme mobilization [38]. This leads us to propose the
following model for NK/MSC interaction (Fig. 7). A complex
two-way interaction occurs between NK cells and allogeneic
MSC (or hUTC). Resting NK cells do not kill allogeneic MSC
regardless of the treatment of MSC. In contrast (IL-2/15), ac-
tivated NK cells kill resting MSC via the NKG2D/Perforin/
Granzyme pathway; in addition, the killing of hUTC is sup-
ported by CD54/ICAM-1 engagement and occurs more
readily. IFN-g (a product of NK activation) ‘‘licenses’’ or ren-
ders MSC or hUTC more resistant to killing, and this is, in
part, due to expression of MHC class I (HLA-ABC) by the
MSC or hUTC. In the opposite direction, MSC affect NK ac-
tivation. MSC block IL-2/IL-15 driven activation of NK cells
through prostaglandin secretion. This is enhanced by IFN-g
stimulation of MSC to express the tryptophan degrading en-
zyme, IDO, which affords an alternative mechanism of NK
suppression. Thus, while NK cells can kill MSC, this is limited
and dependent on the activation status of both cell types. The
implications for cell therapy of this model are that hUTC or
MSC entering a site of inflammation will likely be licensed
and rendered resistant to NK deletion unless high numbers of
activated NK cells are present. In this scenario, hUTC or MSC
will tend to block further NK activation and have an anti-
inflammatory effect. In contrast, in the absence of systemic
inflammation, hUTC or MSC that encounter activated NK
cells at non-inflamed sites will be deleted through lysis. Thus,
the persistence of hUTC or MSC cell therapy will vary with
the nature of inflammation and the site examined.
In conclusion, our data reveal the intricate relationship that
exists between allogeneic hUTC or MSC and NK cells. It de-
ciphers the mechanisms employed by IFN-g- stimulated
hUTC or MSC in mediating NK suppression, as well as
evading NK deletion. Since there have always been issues
regarding the efficacy of cell-based therapies [35,47], this study
suggests that simple manipulation of hUTC/MSC during
culture and cell source selection in the ligands identified here
FIG. 7. Proposed model for the interaction between NK
cells and hUTC or MSC. Resting NK cells do not kill hUTC/
MSC effectively, whereas IL-2/IL-15-activated NK cells kill
resting cells via an NKG2D pathway. IFN-g- stimulated
hUTC/MSC are less susceptible to this killing due to ele-
vated MHC-I expression. IFN-g is a product of NK cell ac-
tivation (not shown for clarity). However, hUTC/MSC also
affect IL-2/IL-15-driven NK cell activation through prosta-
glandin production. This is enhanced by IFN-g stimulation,
which induces IDO and further suppresses NK activation.
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may result in the development of more effective cell-based
therapies that avoid the confounding effects of NK deletion.
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